Spero Therapeutics Accelerates Growth with Landmark FDA Approval and Strategic Partnerships
Spero Therapeutics has made significant strides in the second quarter of 2026, with a series of major milestones that underscore its commitment to advancing innovative treatments for patients. On June 17th, the US Food and Drug Administration (FDA) approved Utebzi, the first and only oral carbapenem for the treatment of complicated urinary tract infections, including pyelonephritis.
This approval was based on the results of the phase III PIVOT-PO study, which demonstrated the efficacy and safety of Utebzi in patients with limited or no alternative oral treatments. GSK holds exclusive commercialization rights worldwide, excluding certain Asian territories where Meiji retains rights. The company expects Utebzi to be available to US patients in the second half of this year.
The approval of Utebzi marks a significant achievement for Spero Therapeutics, which has invested over a decade in developing this asset. According to Esther Rajavelu, President and Chief Executive Officer, 'Utebzi's approval provided us with an opportunity to pursue other growth prospects in immunological diseases with high unmet medical need.' This strategic shift is reflected in the company's announcements in July.
On July 8th, Spero Therapeutics announced an exclusive license agreement with Innovent Biologics for SP001, also known as IBI355. Under this agreement, the company gains exclusive worldwide rights (excluding Greater China) to develop and commercialize SP001 for all indications. The deal is valued at approximately $1.1 billion in total contingent deal value.
In addition to this partnership, Spero Therapeutics closed a $105 million non-dilutive, non-recourse royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR. This funding will support the company's growth prospects and enable it to advance its pipeline of innovative treatments.
The appointment of Dr. Debra Jeske Zack as Chief Medical Officer also marks an important milestone for Spero Therapeutics. With over 25 years of experience in developing therapeutics for immune-mediated diseases, Dr. Jeske Zack brings a wealth of expertise to the company. Esther Rajavelu welcomed her to the team and praised her leadership skills, saying 'We are so glad you are here and look forward to your comments on SP001 later during this call.'
The second quarter has been marked by significant progress for Spero Therapeutics. The approval of Utebzi, combined with strategic partnerships and new funding, positions the company for future growth. As Esther Rajavelu noted, 'We have made great strides in advancing our pipeline and executing on our strategy to build a sustainable business model that can drive long-term value creation.'
With these developments, Spero Therapeutics is poised to make a meaningful impact in the field of immunological diseases, where there remains significant unmet medical need. The company's commitment to innovation and its pursuit of new growth prospects will undoubtedly shape the future of healthcare.
